Telotristat ethyl is approved to treat carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy. In the Phase 3, randomized, placebo-controlled, double-blind TELESTAR study, patients with carcinoid syndrome experiencing ≥4 bowel movements (BMs) per day while on SSA therapy were treated with telotristat ethyl 250 mg 3 times per day (tid), telotristat ethyl 500 mg tid, or placebo tid. Time to sustained improvement in BM frequency during the Double-blind Treatment (DBT) period is presented.
BACKGROUND:
Telotristat ethyl is approved to treat carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy. In the Phase 3, randomized, placebo-controlled, double-blind TELESTAR study, patients with carcinoid syndrome experiencing ≥4 bowel movements (BMs) per day while on SSA therapy were treated with telotristat ethyl 250 mg 3 times per day (tid), telotristat ethyl 500 mg tid, or placebo tid. Time to sustained improvement in BM frequency during the Double-blind Treatment (DBT) period is presented.
METHODS:
The time to the first occurrence of sustained response was defined as the time from the first dose to the first day of a continuous 14 days of ≥30% reduction from Baseline in BM frequency during the DBT period. The time to the first sustained response in the TELESTAR study was examined among treatment groups and analyzed using Cox regression to analyze hazard ratios and the logrank test for treatment comparisons.
RESULTS:
Each treatment arm had 45 patients. Sustained improvement in BM frequency over the 12-week DBT period was achieved in 34, 31, and 19 patients
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in the telotristat ethyl 250 mg, telotristat ethyl 500 mg, and placebo groups. Median time to sustained ≥30% improvement was 3-4 weeks with telotristat ethyl at both dosing levels, and no median was reached on placebo (Table  1) . Hazard ratio estimates suggest treatment with telotristat ethyl increases the likelihood of a sustained improvement in BM frequency more than 2-fold as compared with placebo. The first day of sustained improvements in BM frequency occurred within 5 days (25th percentile) and 73 days (75th percentile) of treatment initiation.
CONCLUSION:
Time to sustained clinical benefit with telotristat ethyl may vary across patients. Some patients experienced initiation of sustained improvement in BM frequency within days of beginning telotristat ethyl treatment, whereas the median time on therapy for this effect was 3-4 weeks. 
